Floatz logo

PEGFILGRASTIM

Anterior Urethral Cancer

University of Southern Californiaprotein_peptidePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Anterior Urethral Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
University of Southern California
Phase 2CCC
METHOTREXATE
University of Southern California
Phase 2CCC
VINBLASTINE
University of Southern California
Phase 2CCC
Inno-206
University of Southern California
Phase 2CCC

Same molecule, other indications

PEGFILGRASTIM is also rated in:

Chemotherapy-induced NeutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
neutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →